Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) Analogues

Ipsen470 enrolled

Overview

The intention of this study is to investigate how many patients with prostate cancer, planned to be treated with LHRH analogues without history of surgery or radiotherapy, are suffering from LUTS. In addition the effect of LHRH analogues on the improvement of theses primary LUTS symptoms over time will be investigated.

Study Type

OBSERVATIONAL

Enrollment

470

Conditions

Prostate Cancer

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * Adult men with locally advanced or metastatic prostate cancer scheduled to receive LHRH analogues. A patient who has completed an IPSS questionnaire in his last visit, before the start of LHRH analogues, will be able to participate in the study. This last visit has to be done 6 months before the baseline visit. * Patients having provided written informed consent * Patients mentally fit for completing a self-administered questionnaire Exclusion Criteria: * Any surgical or radiotherapy treatment performed at prostate level before the entry of the study * Patient with castrate levels of testosterone ( \< 50 ng/dL) at his first IPSS questionnaire * Patients who are also participating in any other clinical study within the last 2 months before study entry * Life expectancy of less than 12 months

Locations (32)

Outcomes

Primary Outcomes

The number of patients having Lower Urinary Tract Symptoms (LUTS) at baseline.

Time frame: Baseline

The percentage of patients suffering from prostate cancer with moderate to severe LUTS (International prostate symptom score (IPSS) >7) at baseline and having at least 3 points reduction of IPSS score at the end of study (48 weeks).

Time frame: Week 48

Secondary Outcomes

The percentage of patients suffering from prostate cancer with moderate to severe LUTS (score IPSS > 7) at baseline and having at least 3 points reduction of IPSS score at week 24.

Time frame: Week 24

The correlation between IPSS score changes and total prostatic-specific antigen (PSA) changes after 24 weeks of treatment compared to baseline in patients with non-operable prostate cancer presenting moderate to severe LUTS (score IPSS >7) at baseline.

Assessed with the Pearson correlation coefficient

Time frame: Week 24

The correlation between IPSS score changes and total PSA changes after 48 weeks of treatment compared to baseline in patients with non-operable prostate cancer presenting moderate to severe LUTS (score IPSS >7).

Assessed with the Pearson correlation coefficient

Time frame: Week 48

Comparison of the percentage of patients presenting an IPSS ≥ 3 at week 24 to the percentage of patients presenting an IPSS ≥ 3 at baseline.

Assessed with the McNemar's test

Time frame: Week 24

Comparison of the percentage of patients presenting an IPSS ≥ 3 at week 48 to the percentage of patients presenting an IPSS ≥ 3 at baseline.

Assessed with the McNemar's test

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.